Chairman and CEO of NatureWise Biotech & Medicals, and a key leader at Novelwise Pharmaceuticals.
Education: B.S. in Pharmacy (NTU), MBA (Case Western Reserve University, USA), Ph.D. in Cell Biology (Lanzhou University, China).Experience: Former General Manager at IPS (USA) and White Biotech; founded NatureWise in 2000, leading innovation in drug development.Academic & Professional: Associate Editor of scientific journals, published in healthcare media, holds nearly 30 international patents and multiple scientific papers.

Chief Executive Officer (Headquarters), NovelWise Pharmaceutical Corporation USA
Dr. Keith Chan is the former Director at the U.S. Food and Drug Administration (FDA) and the founder of GlobalMax, a contract research organization specializing in new drug development. He has a successful track record of guiding multiple drug programs through FDA approval. As Executive Managing Director of GlobalMax and Chairman of the Board of NovelWise Pharmaceutical Corporation USA, a wholly owned subsidiary of NovelWise, Dr. Chan brings strategic regulatory insight and operational leadership to advance the company’s clinical and commercial objectives.

Special Advisor to the Chairman, NovelWise Pharmaceutical Corporation USA.

Tai-Sen Soong, Ph.D., is a seasoned venture capitalist with 20+ years of direct investment experiences. He has served as a Managing Director of Imagen Holdings, Natinal University of Singapore, head of life science investments, overseas department, China Development Industrial Bank, founder and CEO of CDIB Bioscience ventures, a spin off fund from the bank, and the founder and CEO/President of Senhwa Biosciences. He is recognized as one of the most successful biotech venture capitalist in Taiwan.

Chief Executive Officer (USA), NovelWise Pharmaceutical Corporation USA
Dr. John Soong is a seasoned, board-certified physician with over 12 years of experience in leading, designing, and overseeing global clinical trials across both early- and late-stage oncology programs. With a strong track record in translational development and strategic execution, Dr. Soong brings deep expertise in advancing innovative cancer therapies from concept to clinic. He currently serves as the Chief Executive Officer of NovelWise Pharmaceutical Corporation USA.

Director of Clinical Operations, NovelWise Pharmaceutical Corporation USA
Dr. Pai holds a Ph.D. in Pharmacology and brings extensive expertise in global clinical trial management and operational strategy, with a strong background in oncology drug development. As Director of Clinical Operations at NovelWise Pharmaceutical Corporation, Dr. Pai leads the planning, execution, and oversight of early- and late-phase clinical trials. Her leadership ensures the seamless coordination of cross-functional teams and CRO partners, with a focus on regulatory compliance, quality, and operational efficiency.

CMC Manager, NovelWise Pharmaceutical Corporation USA
Hanpei Hsu serves as CMC Manager at NovelWise Pharmaceutical Corporation USA, bringing expertise in chemistry, manufacturing, and controls (CMC) for oncology drug development. With solid experience in drug substance and drug product supply chain management, she oversees manufacturing processes, quality standards, and regulatory documentation to ensure reliable and compliant clinical trial material delivery. Her role is pivotal in bridging technical operations with clinical development, enabling efficient and high-quality execution of global studies.